within Pharmacolibrary.Drugs.ATC.S;

model S03AA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.02666666666666667,
    adminDuration  = 600,
    adminMass      = 0.0015,
    adminCount     = 1,
    Vd             = 0.00031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Polymyxin B is a polypeptide antibiotic used as a last-line treatment for multi-drug resistant Gram-negative bacterial infections. It is active against organisms such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae. Polymyxin B is approved for clinical use and is administered mainly in hospital settings for severe infections.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in critically ill adult patients, mean age ~54 years, receiving intravenous polymyxin B for severe bacterial infections.</p><h4>References</h4><ol><li><p>Tran, TB, et al., &amp; Li, J (2016). Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?. <i>International journal of antimicrobial agents</i> 48(6) 592–597. DOI:<a href=&quot;https://doi.org/10.1016/j.ijantimicag.2016.09.010&quot;>10.1016/j.ijantimicag.2016.09.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27793510/&quot;>https://pubmed.ncbi.nlm.nih.gov/27793510</a></p></li><li><p>Kubin, CJ, et al., &amp; Yin, MT (2018). Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. <i>Antimicrobial agents and chemotherapy</i> 62(3) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01493-17&quot;>10.1128/AAC.01493-17</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29311066/&quot;>https://pubmed.ncbi.nlm.nih.gov/29311066</a></p></li><li><p>Yu, Z, et al., &amp; Yu, Y (2025). Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter study. <i>Antimicrobial agents and chemotherapy</i> 69(4) e0185924–None. DOI:<a href=&quot;https://doi.org/10.1128/aac.01859-24&quot;>10.1128/aac.01859-24</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40047414/&quot;>https://pubmed.ncbi.nlm.nih.gov/40047414</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S03AA03;
